Athersys CEO: Trial Results Will Prove Stock Surge Sustainable

Now watching

Next video starts in : 7 Play

Athersys CEO: Trial Results Will Prove Stock Surge Sustainable

Athersys CEO: Trial Results Will Prove Stock Surge Sustainable
Replay video
Up next

Steel Panther - Miley & Billy Ray Cyrus Pour Some Sugar on Steel Panther

Unlock your personal NFL Now stream by signing in to NFL.com

Athersys CEO: Trial Results Will Prove Stock Surge Sustainable

by TheStreet.com Videos 3:05 mins

Athersys CEO: Trial Results Will Prove Stock Surge Sustainable

by TheStreet.com Videos 3:05 mins

Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company's regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company's lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.

Must Watch